Pharmaron extends Decheng II Fund investment period, revises fees

Pharmaron Beijing, as a limited partner, has agreed to extend the investment period of the Hangzhou Decheng II Equity Investment Partnership (Limited Partnership) (referred to as "Decheng II Fund") by one year, moving its expiry from December 29, 2025, to December 29, 2026. This decision, influenced by market conditions and the fund's investment strategy, aims to provide more time and flexibility to identify valuable investment opportunities.

The extension also revises the management fee calculation for this additional year. Management fees will now be calculated based on the total investment cost of all projects held by the partnership on the relevant payment date (after deducting the cost of permanently written-off projects), charged at a rate of 0.5% per quarter. Pharmaron formalized this revision by signing a "Consent Letter" on September 26, 2025.

The company stated that this extension will not incur additional management fees beyond the revised structure and does not harm the interests of the company or its shareholders. Pharmaron acknowledges potential risks associated with project implementation, risk management, and investment returns and will continue to disclose progress in accordance with relevant laws and regulations.